ImmunityBio Shares Surge as EU Approves ANKTIVA for Bladder Cancer

The European Commission’s decision to grant marketing authorization for ANKTIVA (nogapendekin alfa inbakicept-pmln) on February 18, 2026, represents a watershed moment for ImmunityBio, effectively doubling the potential market for its flagship oncology product. The approval specifically targets patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. This regulatory win triggered an immediate and sharp appreciation in ImmunityBio’s stock price on the Nasdaq, as investors reacted to the company’s successful navigation of the rigorous European Medicines Agency (EMA) review process. The transition from a domestic U.S. provider to an international commercial entity is a high-stakes evolution for any biotech, and this approval validates ImmunityBio’s global regulatory strategy and its ability to scale operations across the Atlantic.

At the heart of the excitement is ANKTIVA’s status as a first-in-class IL-15 receptor agonist. Unlike traditional immunotherapies that may broadly stimulate the immune system or remove biological brakes—such as checkpoint inhibitors like Merck's Keytruda—ANKTIVA is a superagonist designed to specifically activate the body’s natural killer (NK) cells and CD8+ killer T cells. By mimicking the biological activity of the IL-15 cytokine, it creates a targeted immune response that is particularly effective in the localized environment of the bladder. The clinical data supporting this approval, largely derived from the QUILT-3.032 trial, demonstrated that the combination of ANKTIVA and BCG could achieve durable complete responses in patients who had otherwise run out of options. For many of these patients, the only remaining alternative would have been a radical cystectomy, a life-altering surgery to remove the bladder entirely. The ability to offer a bladder-sparing treatment is a powerful value proposition in the European healthcare landscape, where quality of life and long-term surgical costs are heavily scrutinized.

“

This regulatory win triggered an immediate and sharp appreciation in ImmunityBio’s stock price on the Nasdaq, as investors reacted to the company’s successful navigation of the rigorous European Medicines Agency (EMA) review process.

The strategic implications of this approval extend far beyond the immediate revenue potential of the European market. By securing a foothold in the EU, ImmunityBio establishes a precedent for its IL-15 platform that could streamline future approvals for other indications. The company is currently investigating the superagonist in several other high-value areas, including non-small cell lung cancer (NSCLC) and Lynch syndrome. The proof-of-concept provided by the NMIBC approval in both the U.S. and the EU strengthens the argument that the IL-15 mechanism is a versatile and potent tool in the oncology toolkit. Furthermore, the approval may act as a catalyst for potential partnership discussions with larger pharmaceutical firms looking to bolster their immunotherapy portfolios with a validated, complementary agent that works synergistically with existing standards of care.